Treg therapy in transplantation: a general overview
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Solid organ transplantation remains the treatment of choice for end-stage organ failure. Whilst the short-term outcomes post-transplant have improved in the last decades, chronic rejection and immunosuppressant side effects remain an ongoing concern. Hematopoietic stem cell transplantation is a well-established procedure for the treatment of patients with haematological disorders. However, donor T cells are continually primed and activated to react against the host causing graft-versus-host disease (GvHD) that leads to tissue damages and death. Regulatory T cells (Tregs) play an essential role in maintaining tolerance to self-antigens, preventing excessive immune responses and abrogating autoimmunity. Due to their suppressive properties, Tregs have been extensively studied for their use as a cellular therapy aiming to treat GvHD and limit immune responses responsible for graft rejection. Several clinical trials have been conducted or are currently ongoing to investigate safety and feasibility of Treg-based therapy. This review summarizes the general understanding of Treg biology and presents the methods used to isolate and expand Tregs. Furthermore, we describe data from the first clinical trials using Tregs, explaining the limitations and future application of these cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608 · cited 2×
“[18] identified for the first time a small population of CD4 cells that expressed high levels of IL-2 a-chain receptor (CD25), whose depletion resulted in autoimmune diseases whilst their”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 4×
“The authors described a procedure and first-in-man clinical effects of adoptive transfer of ex vivo-expanded CD4+CD25+CD127 cells for the treatment of two patients affected by acute and chronic GvHD, respectively.”
BackgroundInfluentialMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 1×
“Furthermore, CTLA-4 can also downregulate DCs’ activity via trans-endocytosis or extraction of CD80 and CD86 resulting in diminished co-stimulation [49].”
BackgroundType 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033 · cited 3×
“developed and tested in type 1 diabetic patients receiving polyclonally expanded Tregs [60].”
BackgroundMethodChaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
Yadav, M., Louvet, C., Davini, D., Gardner, J. M., Martinez-Llordella, M., Bailey-Bucktrout, S., Anthony, B. A., Sverdrup, F. M., Head, R., Kuster, D. J., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120822 · Cited by 649 · cited 1×
“(pTregs) [33,34] in human, this is not possible [35].”
BackgroundToker, A., Engelbert, D., Garg, G., Polansky, J. K., Floess, S., Miyao, T., Baron, U., Düber, S., Geffers, R., Giehr, P., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203473 · Cited by 283 · cited 1×
“the FoxP3 gene locus, which is fully demethylated in tTregs [36].”
BackgroundNeuropilin‐1 is not a marker of human Foxp3 + Treg
Milpied, P., Renand, A., Bruneau, J., Mendes‐Da‐Cruz, D. A., Jacquelin, S., Asnafi, V., Rubio, M., MacIntyre, E., Lepelletier, Y., & Hermine, O. (2009) · European Journal of Immunology · doi:10.1002/eji.200839040 · Cited by 136 · cited 1×
“(pTregs) [33,34] in human, this is not possible [35].”
BackgroundDiscarded Human Thymus Is a Novel Source of Stable and Long-Lived Therapeutic Regulatory T Cells
Dijke, I. E., Hoeppli, R. E., Ellis, T., Pearcey, J., Huang, Q., McMurchy, A. N., Boer, K., Peeters, A. M. A., Aubert, G., Larsen, I., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13456 · Cited by 101
Cited by
Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity
Romano, M., Fanelli, G., Albany, C. J., Giganti, G., & Lombardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00043 · Cited by 512
Self-citationL-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling
Ivetic, A., Hoskins Green, H. L., & Hart, S. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01068 · Cited by 469
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Court, A. C., Le‐Gatt, A., Luz‐Crawford, P., Parra, E., Aliaga‐Tobar, V., Bátiz, L. F., Contreras, R. A., Ortúzar, M. I., Kurte, M., Elizondo‐Vega, R., et al. (2020) · The EMBO Reports · doi:10.15252/embr.201948052 · Cited by 259
“…the survival rate of GVHD mice reducing the degree of tissue inflammation Since CD4 + CD25 + Foxp3 + Treg cells are critical in the control of tolerance and autoimmunity and also implicated in human diseases including GVHD [11], we used this model to assess the functional impact of MitoT in vivo .”
T cell Allorecognition Pathways in Solid Organ Transplantation
Siu, J. H. Y., Surendrakumar, V., Richards, J. A., & Pettigrew, G. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02548 · Cited by 223
Zhang, Q.-Q., Zhang, W.-J., & Chang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168848 · Cited by 24
“In a recent study of a cardiac allograft model, the presence or absence of the HDAC6 molecule alone could determine acute rejection or long-term engraftment (121).”
Background
Metadata
- Authors
- Romano, M., Tung, S. L., Smyth, L. A., & Lombardi, G.
- Venue
- Transplant International
- Publisher
- Frontiers Media SA
- Published
- 2017-02-06
- Volume
- 30
- Issue
- 8
- Pages
- 745-753
- ISSN
- 0934-0874 (ISSN-L)
- OpenAlex
- W2564669868
- Cited by
- 132
- References
- 10
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.